PL1586320T3 - Stała postać dawkowania zawierająca cytyzynę - Google Patents

Stała postać dawkowania zawierająca cytyzynę

Info

Publication number
PL1586320T3
PL1586320T3 PL05472001T PL05472001T PL1586320T3 PL 1586320 T3 PL1586320 T3 PL 1586320T3 PL 05472001 T PL05472001 T PL 05472001T PL 05472001 T PL05472001 T PL 05472001T PL 1586320 T3 PL1586320 T3 PL 1586320T3
Authority
PL
Poland
Prior art keywords
cytisine
dosage form
solid dosage
containing solid
tablets
Prior art date
Application number
PL05472001T
Other languages
English (en)
Inventor
Vesselin Evgeniev Daskalov
Angel Radoslavov Timchev
Violeta Andreeva Pavlova
Radka Kostova Grozdeva
Vlayko Petrov Tonev
Yanka Ivanova Borissova
Dobrina Hristova Dobreva
Todorka Boncheva Bendurska
Original Assignee
Sopharma Ad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sopharma Ad filed Critical Sopharma Ad
Publication of PL1586320T3 publication Critical patent/PL1586320T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05472001T 2004-04-16 2005-02-02 Stała postać dawkowania zawierająca cytyzynę PL1586320T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG108686A BG65536B1 (bg) 2004-04-16 2004-04-16 Лекарствена форма, съдържаща цитизин
EP05472001A EP1586320B1 (en) 2004-04-16 2005-02-02 Cytisine containing solid dosage form

Publications (1)

Publication Number Publication Date
PL1586320T3 true PL1586320T3 (pl) 2008-12-31

Family

ID=34943361

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05472001T PL1586320T3 (pl) 2004-04-16 2005-02-02 Stała postać dawkowania zawierająca cytyzynę

Country Status (6)

Country Link
EP (1) EP1586320B1 (pl)
AT (1) ATE401075T1 (pl)
BG (1) BG65536B1 (pl)
DE (1) DE602005008128D1 (pl)
PL (1) PL1586320T3 (pl)
SI (1) SI1586320T1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL220354B1 (pl) 2012-11-19 2015-10-30 Aflofarm Fabryka Leków Spółka Z Ograniczoną Odpowiedzialnością Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
PL408608A1 (pl) 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN110088106A (zh) 2016-08-19 2019-08-02 布里斯托大学 化合物
CA3070055A1 (en) * 2017-07-24 2019-01-31 Achieve Pharma Uk Limited Cytisine salts
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
DK1178045T3 (da) * 1997-04-09 2003-06-23 Pfizer Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler

Also Published As

Publication number Publication date
BG108686A (en) 2005-12-30
DE602005008128D1 (de) 2008-08-28
ATE401075T1 (de) 2008-08-15
EP1586320A1 (en) 2005-10-19
SI1586320T1 (sl) 2009-02-28
EP1586320B1 (en) 2008-07-16
BG65536B1 (bg) 2008-11-28

Similar Documents

Publication Publication Date Title
SI1586320T1 (sl) Citizin vsebujoäś trdne dozirne oblike
UA108594C2 (uk) Одинична дозована фармацевтична форма
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
MY139913A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
IL181382A0 (en) Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
HK1096034A1 (en) A solid dosage form comprising a fibrate
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
AP2003002763A0 (en) Controlled release formulations for oral administration
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
WO2006020522A3 (en) Multiplex drug delivery device
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
IL150528A0 (en) Ibuprofen containing active agent preparation
ZA200506992B (en) Fibrate tablet and method for the production thereof
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2005082331A3 (en) Extended release tablets of clarithromycin
MY141008A (en) Oral formulations of deoxypeganine and their uses
WO2004014318A3 (en) Levothyroxine compositions and methods
WO2003013441A3 (en) Levothyroxine compositions and methods
PL1499278T3 (pl) Farmaceutyczna postać użytkowa o natychmiastowym uwalnianiu zawierająca polimorficzny tibolon
WO2008147245A3 (fr) Composition pharmaceutique de proxodolol à libération contrôlée